Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Byrne, G. Targher (2020)
NAFLD as a driver of chronic kidney disease.Journal of hepatology
A. Mantovani, G. Zaza, C. Byrne, A. Lonardo, G. Zoppini, E. Bonora, G. Targher (2018)
Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis.Metabolism: clinical and experimental, 79
J. Nagy, T. Kovács (2019)
A brief review on the rising incidence of chronic kidney diseases and non-alcoholic fatty liver disease.Physiology international, 106 4
CP Cannon, V Perkovic, R Agarwal (2020)
Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c, 141
D. Sinn, D. Kang, H. Jang, Seonhye Gu, S. Cho, S. Paik, S. Ryu, Yoosoo Chang, M. Lazo, E. Guallar, Juhee Cho, G. Gwak (2017)
Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study.Journal of hepatology, 67 6
J. Ix, K. Sharma (2010)
Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK.Journal of the American Society of Nephrology : JASN, 21 3
B. Neuen, T. Ohkuma, B. Neal, D. Matthews, D. Zeeuw, K. Mahaffey, G. Fulcher, Qiang Li, M. Jardine, Richard Oh, H. Heerspink, V. Perkovic (2019)
Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.Journal of the American Society of Nephrology : JASN
C. Cannon, V. Perkovic, R. Agarwal, J. Baldassarre, G. Bakris, D. Charytan, D. Zeeuw, Robert Edwards, T. Greene, H. Heerspink, M. Jardine, A. Levin, Jingwei Li, B. Neal, C. Pollock, D. Wheeler, Hong Zhang, B. Zinman, K. Mahaffey (2019)
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial.Circulation
P. Angulo, J. Hui, G. Marchesini, E. Bugianesi, J. George, G. Farrell, F. Enders, S. Saksena, A. Burt, J. Bida, K. Lindor, S. Sanderson, M. Lenzi, L. Adams, J. Kench, T. Therneau, C. Day (2007)
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLDHepatology, 45
(2020)
Clinical implications of basic research nephron protection in diabetic kidney disease
M. Praga, E. Morales (2016)
The Fatty Kidney: Obesity and Renal DiseaseNephron, 136
M. Bertolotti, A. Lonardo, C. Mussi, E. Baldelli, E. Pellegrini, S. Ballestri, D. Romagnoli, P. Loria (2014)
Nonalcoholic fatty liver disease and aging: epidemiology to management.World journal of gastroenterology, 20 39
A. Mantovani, C. Zusi, A. Dalbeni, G. Grani, E. Buzzetti (2019)
Risk of kidney dysfunction in NAFLD.Current pharmaceutical design
G. Targher, S. Francque (2017)
A fatty liver leads to decreased kidney function?Journal of hepatology, 67 6
G. Targher, L. Bertolini, S. Rodella, G. Lippi, G. Zoppini, M. Chonchol (2010)
Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis.Clinical journal of the American Society of Nephrology : CJASN, 5 12
M. Talim (2007)
Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic PatientsDiabetes Care, 30
Ofri Mosenzon, S. Wiviott, Avivit Cahn, Aliza Rozenberg, Ilan Yanuv, Erica Goodrich, S. Murphy, H. Heerspink, Thomas Zelniker, J. Dwyer, Deepak Bhatt, Lawrence Leiter, D. McGuire, John Wilding, Eri Kato, I. Gause-Nilsson, M. Fredriksson, P. Johansson, A. Langkilde, M. Sabatine, I. Raz (2019)
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.The lancet. Diabetes & endocrinology
Jia Fu, Kyung Lee, Peter Chuang, Zhihong Liu, J. He (2015)
Glomerular endothelial cell injury and cross talk in diabetic kidney disease.American journal of physiology. Renal physiology, 308 4
F García-Martín, E González Monte, E Hernández Martínez (2020)
Cu�ndo realizar biopsia renal en pacientes con diabetes mellitus tipo 2? Modelo predictivo de enfermedad renal no diab�tica, 40
G. Targher, C. Byrne (2017)
Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney diseaseNature Reviews Nephrology, 13
G. Targher, M. Chonchol, L. Bertolini, S. Rodella, L. Zenari, G. Lippi, M. Franchini, G. Zoppini, M. Muggeo (2008)
Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease.Journal of the American Society of Nephrology : JASN, 19 8
S. Romeo, J. Kozlitina, Chao Xing, A. Pertsemlidis, David Cox, L. Pennacchio, E. Boerwinkle, Jonathan Cohen, H. Hobbs (2008)
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver diseaseNature genetics, 40
I. Boer, M. Caramori, J. Chan, H. Heerspink, Clint Hurst, K. Khunti, A. Liew, E. Michos, S. Navaneethan, W. Olowu, Tami Sadusky, N. Tandon, K. Tuttle, C. Wanner, K. Wilkens, S. Zoungas, L. Lytvyn, J. Craig, J. Craig, D. Tunnicliffe, D. Tunnicliffe, M. Howell, M. Howell, M. Tonelli, Michael Cheung, A. Earley, P. Rossing (2020)
Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: Evidence-based advances in monitoring and treatment.Kidney international
M. Goligorsky (2017)
Vascular endothelium in diabetes.American journal of physiology. Renal physiology, 312 2
E. O’Sullivan, J. Hughes, D. Ferenbach (2017)
Renal Aging: Causes and Consequences.Journal of the American Society of Nephrology : JASN, 28 2
A. Mantovani, T. Turino, Maria Lando, K. Gjini, C. Byrne, C. Zusi, F. Ravaioli, A. Colecchia, C. Maffeis, G. Salvagno, G. Lippi, E. Bonora, G. Targher (2019)
Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes.Diabetes & metabolism
Abeba Berhane, E. Weil, W. Knowler, Robert Nelson, Robert Hanson (2011)
Albuminuria and estimated glomerular filtration rate as predictors of diabetic end-stage renal disease and death.Clinical journal of the American Society of Nephrology : CJASN, 6 10
H. Anders, T. Huber, B. Isermann, M. Schiffer (2018)
CKD in diabetes: diabetic kidney disease versus nondiabetic kidney diseaseNature Reviews Nephrology, 14
Sheila Bermejo, C. García-Carro, M. Soler (2019)
Diabetes and renal disease-should we biopsy?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Florencio García-Martín, E. Monte, Eduardo Martínez, Teresa Boch, Norman Jiménez, M. Terente (2019)
When to perform renal biopsy in patients with type2 diabetes mellitus? Predictive model of non-diabetic renal disease.Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia
G. Targher, M. Chonchol, C. Byrne (2014)
CKD and nonalcoholic fatty liver disease.American journal of kidney diseases : the official journal of the National Kidney Foundation, 64 4
M. Cooper, S. Inzucchi, B. Zinman, S. Hantel, M. Eynatten, C. Wanner, Audrey Koitka‐Weber (2019)
Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation
F. Macaluso, M. Maida, S. Petta (2015)
Genetic background in nonalcoholic fatty liver disease: A comprehensive review.World journal of gastroenterology, 21 39
R. Alicic, M. Rooney, K. Tuttle (2017)
Diabetic Kidney Disease: Challenges, Progress, and Possibilities.Clinical journal of the American Society of Nephrology : CJASN, 12 12
BackgroundThe increasing prevalence of type 2 diabetes mellitus (T2DM) has influenced in an increasing prevalence of chronic kidney disease (CKD). Little is known about the influence of non-alcoholic fatty liver disease (NAFLD) on the progression of CKD. The aim of this study was to analyse the role of NAFLD and its severity in the progression of renal function in patients with T2DM.MethodsWe conducted a retrospective and observational study including patients with T2DM and estimated glomerular filtration rate (eGFR) >30 mL/min/1.73 m2. NAFLD was defined as the presence of compatible ultrasonography and/or the presence of fibrosis using the NAFLD score. Patients were classified into three groups according to the NAFLD score: Group 1: <−1.85; Group 2: −1.85–0.18 and Group 3: >0.18.ResultsA total of 102 patients were included [67.6% males, median age 59 years [interquartile range (IQR) 53–64)], with a median time of T2DM evolution of 70 months (IQR 39–131). Group 3 had lower eGFR (84.8 ± 40.4 versus 71.4 ± 30.6 mL/min/1.73 m2; P = 0.03) and higher proteinuria at baseline (0.56 ± 0.77 versus 1.59 ± 2.70 g/24 h; P = 0.05). After a follow-up time of 75.8 ± 23.9 months, Group 3 had a significant decrease in eGFR (66.6 ± 33.3 versus 36.8 ± 23.1 mL/min/1.73 m2; P ≤ 0.01) and a higher risk of CKD progression [odds ratio 7.50 (95% confidence interval 2.76–20.35); P ≤ 0.001] defined as a decrease in eGFR of >50%.ConclusionsThe presence of NAFLD with high-risk fibrosis confers higher risk of CKD progression in patients with T2DM. Therefore NAFLD should be a risk factor evaluated in these patients to optimize treatment.
Nephrology Dialysis Transplantation – Oxford University Press
Published: May 13, 2021
Keywords: chronic renal insufficiency; diabetes mellitus; diabetic kidney disease; non-alcoholic fatty liver disease; obesity
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.